Overview

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study is being done to test the safety and effectiveness of the combination of intravenous (IV) romidepsin and/or oral 5-azacitidine with IV MK-3475 in people with microsatellite stable (MSS) advanced colorectal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Celgene Corporation
Merck Sharp & Dohme Corp.
Treatments:
Azacitidine
Pembrolizumab
Romidepsin